Silence Therapeutics plc Company Analysis & Research
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. The company leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver.
Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. The company has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.
Company Overview
Founded: 1994. Headquarters: London, United Kingdom. Market Cap: $287M (as of March 2026). Ticker: SLN (NASDAQ).
Industry
Biotechnology - RNA Therapeutics / Genetic Medicine
Cyborg Score: 6/10 — Solid
siRNA platform with meaningful partnerships and Phase II validation offers growth potential, but clinical-stage risk profile requires near-term data milestones for sustained momentum.
Silence is a clinical-stage biotech with differentiated siRNA technology and high-value pharma partnerships, but carries typical biotech execution and capital requirements risks. Recent Phase II data for lead cardiovascular program provides validation, but multiple programs remain early stage with regulatory and clinical uncertainties ahead.
Key Strategic Insights for Silence Therapeutics plc
- Lead program Zerlasiran (SLN360) in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a)
- Strategic partnership with AstraZeneca for siRNA therapeutics across cardiovascular, renal, metabolic, and respiratory disease areas
- Divesiran (SLN124) in Phase I clinical trial for genetic hematological conditions including polycythemia vera
- Clinical-stage biotech dependent on successful trial outcomes and regulatory approvals for pipeline programs
Recent Developments
- (February 2025) Q4 2024 earnings call conducted with recent Phase 2 ALPACAR-360 study data for zerlasiran in ASCVD patients
- (September 2025) Presentation at Morgan Stanley 23rd Annual Global Healthcare Conference
- (2024) Continued advancement of Divesiran and SLN548 programs in development
Competitors & Competitive Landscape
- Ionis Pharmaceuticals — Leading antisense and siRNA therapeutic developer
- Arcturus Therapeutics — RNA therapeutics and delivery platform developer
- AstraZeneca — Pharma partner on Silence's cardiovascular program expansion
Silence Therapeutics is a biotechnology company and leader dedicated in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company competes in the siRNA therapeutic space alongside other RNAi developers and traditional pharma, differentiated by its proprietary mRNA GOLD platform and delivery technology. Strategic partnerships with major pharma like AstraZeneca enhance competitive positioning.
More Company Research
Emperor Watch & Jewellery Limited RxSight, Inc. Osaka Steel Co., Ltd. Arvind Limited Ramaco Resources, Inc. Morinaga Milk Industry Co., Ltd. LG Household & Health Care Carl Zeiss Meditec AG Gates Industrial Corporation plc Konecranes Plc Kaspi.kz Joint Stock Company Ambev S.A. EROAD Limited Edia Co., Ltd. Drilling Tools International CorporationFull Company Research Reports
Looking for a more in-depth analysis of Silence Therapeutics plc? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.